ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Oncology Times Broadcast News with the Audio Journal of Oncology - February 2009"
Episode Synopsis
ONCOLOGY TIMES BROADCAST NEWS WITH THE AUDIO JOURNAL OF ONCOLOGY
February 2009
Peter Goodwin interviews more speakers from the 50th American Society of Hematology Annual Meeting, San Francisco, December 6-9, 2008
IN THIS EDITION:
Greater Role for Umbilical Cord Blood in Adult Transplants
Mary Eapen, Medical College of Wisconsin, Milwaukee
COMMENT: Armand Keating, University of Toronto
Ex Vivo Expansion Of Cord Blood Derived Progenitor Cells: Patient Transplant Data
Colleen Delaney, Fred Hutchinson Cancer Research Center, Seattle
COMMENT: Armand Keating
Erythropoiesis Stimulating Agents in Cancer Patients: Meta-Analysis Mortality Findings
Julia Bohlius, University of Bern
ON BEHALF OF: Erythropoiesis Stimulating Agents Individual Patient Data (EPO IPD) Meta-Analysis Collaborative Group
COMMENTS: Linda Burns, University of Minnesota, Minneapolis
George Canellos, Dana-Farber Cancer Institute, Boston
Imatinib: Durable Responses And Survival in Chronic Myeloid Leukemia: 7-Year IRIS Study Results; Can Imatinib Be Stopped?
Stephen O'Brien, Newcastle University, England
February 2009
Peter Goodwin interviews more speakers from the 50th American Society of Hematology Annual Meeting, San Francisco, December 6-9, 2008
IN THIS EDITION:
Greater Role for Umbilical Cord Blood in Adult Transplants
Mary Eapen, Medical College of Wisconsin, Milwaukee
COMMENT: Armand Keating, University of Toronto
Ex Vivo Expansion Of Cord Blood Derived Progenitor Cells: Patient Transplant Data
Colleen Delaney, Fred Hutchinson Cancer Research Center, Seattle
COMMENT: Armand Keating
Erythropoiesis Stimulating Agents in Cancer Patients: Meta-Analysis Mortality Findings
Julia Bohlius, University of Bern
ON BEHALF OF: Erythropoiesis Stimulating Agents Individual Patient Data (EPO IPD) Meta-Analysis Collaborative Group
COMMENTS: Linda Burns, University of Minnesota, Minneapolis
George Canellos, Dana-Farber Cancer Institute, Boston
Imatinib: Durable Responses And Survival in Chronic Myeloid Leukemia: 7-Year IRIS Study Results; Can Imatinib Be Stopped?
Stephen O'Brien, Newcastle University, England
More episodes of the podcast Oncology Times Broadcast News
Bevacizumab Did Not Improve Disease-Free Survival In Adjuvant Therapy For Early Colon Cancer
28/09/2009
Metastatic Colorectal Cancer: Capecitabine Equivalent to 5-FU in Irinotecan/Bevacizumab Combos
28/09/2009
In God we trust